CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2020

Albany, NY -- (SBWire) -- 07/21/2015 --The pain, nausea, and vomiting endured by a patient undergoing chemotherapy can be extremely debilitating. The number of medications that the healthcare industry provides today can help with CINV, but do very little to negate the symptoms. 2012 witnessed nearly 14.1 million people being diagnosed with cancer, in comparison to the 12.7 million in 2008. With the current rate in mind, the number is expected to reach 17.1 cancer patients by 2020. Their growing numbers will generate a high demand from the healthcare industry for chemotherapy and related markets, including the CINV drugs segment. With almost 70% to 80% of chemotherapy patients experiencing nausea and vomiting, it has become imperative to create stark improvements in the CINV existing and pipeline drugs market.

Browse Full Global CINV Existing and Pipeline Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/cinv-market.html

CINV Existing and Pipeline Drugs Market Segmentation

The single strongest point of differentiation in the market today is the association of major drugs with their revenues earned. The list includes:

Akynzeo (netupitant-palonosetron)
Kytril Generic (granisetron)
Aloxi (palonosetron)
Zofran Generic (ondansetron)
SUSTOL (extended release granisetron injection)
Rolapitant
Emend (aprepitant)

Rolapitant and SUSTOL (APF-530) are newly approved drugs that are set to drive the CINV drugs market till 2020. They show a far stronger efficacy than the current line of CINV drugs, in terms of their medical trials. Their launch is expected to provide a boost to the CINV drugs market and encourage physicians to prescribe the new drugs with a higher confidence.

One the other hand, drugs such as Aloxi and Emend are about to lose their patents to expiration. This will have a significant impact on the CINV existing and pipeline drugs market, which will be flooded with generic drugs with the same chemical formula. The market's revenue is expected to go down largely due to this within a forecast period of 2014 to 2020.

Browse Full Press Release: http://www.transparencymarketresearch.com/pressrelease/cinv-market.htm

Geographical Segmentation

The four prime regions associated with the CINV existing and pipeline drugs market are North America, Asia Pacific, Europe, and the Rest of the World. Of these, North America has held the leading position in the market in 2013 by generating the largest revenue. The region is expected to stay as the market leader till 2020.

The second largest region in the CINV existing and pipeline drugs market is Europe. An average delay of one year is usually experienced by European healthcare facilities in the launch of CINV drugs in comparison to North America. The delays in release of Aloxi and Emend are something that can be used to predict the region's future in the market.

Asia Pacific is expected to play a key role in the CINV existing and pipeline drugs market in the coming years. The emerging economies of China and India, along with a growing prevalence of cancer in the Asia Pacific populace are bound to set the foundations of a strong CINV existing and pipeline drugs market. The emerging nations are fast on the tracks of establishing increasingly efficient healthcare infrastructures. The eventual inclusion of more effective CINV drugs will drive the region's market further.

Key Companies

Most of the top players in the CINV existing and pipeline drugs market are based in North America and Europe. The list includes: Heron Therapeutics, Inc., GlaxoSmithKline plc, Tesaro, Inc., Merck & Co., and Helsinn Holding SA. Most of the top companies hold patented drugs in the CINV existing and pipeline drugs market. Apart from them, the big companies that manufacture generic drugs are Sun Pharma, Barr Laboratories, Baxter Healthcare, Mylan Pharmaceuticals, Inc., Sandoz (Novartis AG), Teva Pharmaceuticals, and Orchid Healthcare.

In conclusion, the CINV existing and pipeline drugs market can expect steady growth due to the rising incidences of caner and the arrival of new and more efficient patented drugs. The market faces the challenge of patent expiration and the efficacy of new patented drugs shall determine its growth.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr.Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com